Skip to main content

Table 1 Baseline clinical and biochemical characteristics of Chinese type 2 diabetic patients with no history of cardiovascular disease (CVD) divided according to the development of CVD during 4.9 (2.8-7.0) years of follow-up

From: Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study

  Non-CVD (n = 4150) CVD (n = 371)  
  median or% IQR* median or% IQR* P value
Age (years) 54 21 64 16 <.0001‡
Male Gender 45.7% (1898)   52.8% (196)   .0086
Smoking status      <.0001†
   Ex smoker 13.3% (553)   20.2% (75)   
   Current smoker 14.9% (620)   21.2% (78)   
Waist circumference (men, cm) 87.5 12.5 88.0 11.0 .2384
Waist circumference (women, cm) 82.5 13.0 84.5 13.0 .0165
Body mass index (kg/m2) 24.6 5.0 24.9 4.3 .4409
Duration of diabetes (Years) 5 9 9 10 <.0001‡
Systolic blood pressure (mmHg) 132 25 141 25 <.0001‡
Diastolic blood pressure (mmHg) 75 14 75 13 .1313‡
HbA1c (%) 7.2 2.1 7.7 2.6 <.0001‡
Spot urine albumin creatinine ratio (mg/mmol) 1.55 5.75 7.13 54.8 <.0001‡
eGFR (ml min-1 1.73 m-2) ξ 109 39 93 41 <.0001‡
LDL-C (mmol/L) 3.1 1.2 3.4 1.3 <.0001‡
   ≥3.0 mmol/L 56.1%(2330)   69.0%(256)   <.0001†
HDL-C (mmol/L) 1.28 0.45 1.18 0.45 <.0001‡
   HDL-C <1.0 in male or 1.3 in female 23.8%(987)   25.9%(96)   .3655†
Triglyceride (mmol/L) 1.27 0.97 1.40 1.01 .0031‡
Drug use at enrolment      
Use of antihypertensive drugs at enrolment 29.7%(1231)   42.3%(157)   <.0001†
Drug use during follow-up      
Use of statins during follow-up 22.7%(942)   22.6%(84)   .9799†
Use of fibrates during follow-up 6.41%(266)   4.58%(17)   .1639†
Use of other lipid lowering drugs during follow-up 0.29% (12)   0.27% (1)   .3832 ††
Use of RAS inhibitors during follow-up 48.9% (2029)   62.5% (232)   <.0001†
Use of gliclazide during follow-up 43.7% (1814)   37.2% (138)   .0152†
Use of rosiglitazone during follow-up 4.9% (204)   1.6% (6)   .0038†
Use of other oral antidiabetic drugs during follow-up 79.0% (3280)   80.3% (298)   .5587†
Use of insulin during follow-up 32.4%(1345)   45.0%(167)   <.0001†
Events during follow-up      
Death during follow-up 5.42% (225)   27.5%(102)   <.0001†
  1. *, Median (IQR = interquartile range); †, derived from Chi-square test; ††, Derived from Fisher's exact test; ‡, derived from Wilcoxon two-sample test; ξ, eGFR = glomerular filtration rate from modified MDRD formula; ¶, including drug use at enrolment except for statins and fibrates (users at enrolment were excluded)